Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: koseoglu m. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Sen S, Karabudak R, Schiavetti I, Demir S, Ozakbas S, Tutuncu M, Petek Balci B, Turan OF, Uzunkopru C, Koseoglu M, Yetkin MF, Gunduz T, Gumus H, Kale Icen N, Carmisciano L, Terzi M, Acar P, Gungor Dogan I, Baba C, Tuncer A, Uygunoglu U, Sormani MP, Efendi H, Siva A; Turkish MS Study Group. Sen S, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2021 Jul;52:102968. doi: 10.1016/j.msard.2021.102968. Epub 2021 Apr 18. Mult Scler Relat Disord. 2021. PMID: 33940495 Free PMC article.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Sen S, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19. Mult Scler Relat Disord. 2022. PMID: 35216782 Free PMC article.
The effect of cognitive performance on self-management behavior of multiple sclerosis patients.
Efendi H, Ünal A, Akçalı A, Altunan B, Bingöl A, Altunrende B, Köseoğlu M, Deringöl D, Uzunköprü C, Eğilmez C, Balcı FB, Akman G, Tarhan KG, Gündoğdu AA, Ertürk S, Beckmann Y. Efendi H, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2022 Jul;63:103880. doi: 10.1016/j.msard.2022.103880. Epub 2022 May 19. Mult Scler Relat Disord. 2022. PMID: 35613508
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Tuncer MA, Kürtüncü M, Terzi M, Uygunoğlu U, Göncüoğlu C, Yüceyar AN, Ekmekçi Ö, Türkoğlu R, Soysal A, Köseoğlu M, Boz C, Beckmann Y, Turan ÖF, Demirkıran DM, Akman FG, Altunrende B, Cantürk İA, Birday E, Özcan A, Kamişli Ö, Özen NPA, Çelik RGG, Balcı FB, Efendi H, Sarıkaya C, Akçalı A, Toprak MK, Kabay SC, Kızılay F, Sevim MS, Gazaloğlu GB, Demir CF, Balgetir F, Kıylıoğlu N, Sarıahmetoğlu H, Ölmez Ç, Mavi K, Yüksel S, Işık N, Saip S, Karabudak R, Siva A, Eraksoy M. Tuncer MA, et al. Among authors: koseoglu m. Turk J Med Sci. 2023 Feb;53(1):323-332. doi: 10.55730/1300-0144.5588. Epub 2023 Feb 22. Turk J Med Sci. 2023. PMID: 36945929 Free PMC article.
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M, Demir S, Arslan G, Dinç Ö, Şen S, Gündüz T, Uzunköprü C, Gümüş H, Tütüncü M, Akçin R, Özakbaş S, Köseoğlu M, Bünül SD, Gezen O, Tezer DÇ, Baba C, Özen PA, Koç R, Elverdi T, Uygunoğlu U, Kürtüncü M, Beckmann Y, Doğan İG, Turan ÖF, Boz C, Terzi M, Tuncer A, Saip S, Karabudak R, Kocazeybek B, Efendi H, Bilge U, Siva A. Tütüncü M, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2023 Jul;75:104761. doi: 10.1016/j.msard.2023.104761. Epub 2023 May 10. Mult Scler Relat Disord. 2023. PMID: 37247488 Free PMC article.
Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting.
Altunan B, Ünal A, Efendi H, Köseoğlu M, Terzi M, Kotan D, Tamam Y, Boz C, Güler S, Turan ÖF, Altunrende B, Balcı FB, Turgut N, Akçalı A, Yildirim KA, Günal Dİ, Sunter G, Bingöl A. Altunan B, et al. Among authors: koseoglu m. Mult Scler Relat Disord. 2023 Sep;77:104880. doi: 10.1016/j.msard.2023.104880. Epub 2023 Jul 12. Mult Scler Relat Disord. 2023. PMID: 37459716
The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis.
Şen S, Arslan G, Tütüncü M, Demir S, Dinç Ö, Gündüz T, Uzunköprü C, Gümüş H, Tütüncü M, Akçin R, Özakbaş S, Köseoğlu M, Bünül SD, Gezer O, Tezer DÇ, Baba C, Özen PA, Koç R, Elverdi T, Uygunoğlu U, Kürtüncü M, Beckmann Y, Doğan İG, Turan ÖF, Boz C, Terzi M, Tuncer A, Saip S, Karabudak R, Kocazeybek B, Efendi H, Bilge U, Siva A. Şen S, et al. Among authors: koseoglu m. Noro Psikiyatr Ars. 2023 Aug 10;60(3):252-256. doi: 10.29399/npa.28503. eCollection 2023. Noro Psikiyatr Ars. 2023. PMID: 37645088 Free PMC article.
106 results